Literature DB >> 16091077

Treatment of intestinal perforation in extremely low-birthweight infants.

Akihiro Kawakami1, Yoshitsugu Shirakawa, Akira Shirahata, Kouichi Yano, Masaru Morita, Kimimasa Yasumoto.   

Abstract

BACKGROUND: The mortality of intestinal perforation in extremely low-birthweight infants (ELBWI) is high. It still remains to be determined whether peritoneal drainage is a definitive treatment instead of laparotomy. The authors used bedside peritoneal drainage (BSPD) as the diagnostic procedure, and exchange transfusion (ET) as the preparatory procedure for invasive stress of laparotomy. The treatment protocol is composed primarily of laparotomy combined with BSPD and ET.
METHODS: ELBWI who developed intestinal perforation during hospitalization between 1993 and 2000 were treated according to the aforementioned protocol. Their medical records were examined retrospectively.
RESULTS: Eight ELBWI were identified. The subjects' birthweights ranged from 553 to 892 g and the gestational age ranged from 23 to 26 weeks. The subjects consisted of five cases with idiopathic intestinal perforation, two cases with necrotizing enterocolitis, and one case with meconium plug syndrome. Laparotomy was performed in all cases, and BSPD was performed in seven cases. Intestinal perforation was definitively diagnosed by X-ray only in three cases, while by stool-like drainage in BSPD in the other five cases. Seven (87.5%) cases survived.
CONCLUSION: In this limited experience, the treatment mainly composed of laparotomy combined with BSPD and ET appeared beneficial.

Entities:  

Mesh:

Year:  2005        PMID: 16091077     DOI: 10.1111/j.1442-200x.2005.02100.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  1 in total

1.  Usefulness of peritoneal drainage in extremely low birth weight infants with intestinal perforation: a single-center experience.

Authors:  Ju Yeon Lee; Jung-Man Namgoong; Seong Chul Kim; Dae Yeon Kim
Journal:  Ann Surg Treat Res       Date:  2020-02-28       Impact factor: 1.859

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.